U ntil 1980, any enterically transmitted viral hepatitis was explained as a hepatitis A virus (HAV) infection. However, 25 years after the first welldocumented water-borne hepatitis epidemic that occurred in New Delhi in [1955] [1956] , it was shown that the causative agent of this outbreak was etiologically distinct from both HAV and hepatitis B virus (HBV). Hence, it was labeled as enterically transmitted or epidemic non-A, non-B hepatitis. 1 After its partial cloning and sequencing in 1990, the virus was renamed as hepatitis E virus (HEV). 2 Molecular cloning and sequencing of the full-length viral genome was accomplished in 1991. 3 Although HEV was long recognized as a disease confined to developing countries in Africa and Asia, multiple non-travel-associated autochthonous HEV infections have been reported in Europe and the United States during the past decade. [4] [5] [6] Molecular Virology HEV is a small icosahedral, nonenveloped, singlestranded, positive-sense RNA virus of approximately 27-34 nanometers (reviewed in a previous work HEV genome is approximately 7.2 kilobases (kb) long and contains three overlapping open reading frames (ORF1, ORF2, and ORF3) with a short (27-35 nucleotides [nt] long) 5'-methylguanine-capped untranslated region (5' UTR) and a longer (65 to 74 nt long) 3' UTR ending with a poly A-tail 7 ( Fig. 1 ). ORF2 and ORF3 proteins are translated from a separate subgenomic viral RNA. ORF1 is located at the 5' end, encompasses approximately two thirds of the viral genome, and encodes a nonstructural polyprotein that contains domains with methyl transferase, papain-like cysteine protease, RNA helicase, and RNA-dependent RNA polymerase activity. In addition, there is a Y-domain with unknown function, a polyproline-rich hinge region with high sequence variability, and an X or macro domain that may bind poly(ADP-ribose) and could be involved in viral RNA replication and/or transcription ( Fig. 1) . It is currently still unclear whether the ORF1 polyprotein is processed into smaller proteins with a single function. 7 ORF2 is located at the 3' end of the genome and encodes the capsid protein, which contains immunogenic epitopes. ORF2 induces neutralizing antibodies and is a target for vaccine development. 8, 9 ORF3 overlaps with ORF1 by only 1 nt at its 5' end and extensively overlaps with ORF2 at its 3' end. ORF3 encodes a small cytoskeleton-associated phosphoprotein that is involved in virion morphogenesis, but it probably also exerts a variety of other functions that indirectly endow an environment that is supportive to viral infection and replication. 7 Viral particles that are released from infected cells into the plasma seem to be associated with lipid membranes and ORF3 protein. Viral particles isolated from feces of infected patients are not associated with lipids or ORF3, which are probably lost after passage through the bile duct and duodenum, and have a higher density. 7 
Classification
HEV was previously classified as the sole member of the Hepevirus genus of the Hepeviridae family. 10 However with the identification of novel HEV-like viruses in a variety of animals, an adjustment of the taxonomic classification was recently ratified by the International Committee on Taxonomy of Viruses (ICTV). 10 The
Hepeviridae family is now subdivided into two genera: the Orthohepevirus that comprise all mammalian and avian HEV isolates and the Piscihepevirus that comprises the cutthroat trout virus. The Orthohepevirus is further subdivided into four species: Orthohepevirus A (comprising human, pig, wild boar, deer, mongoose, rabbit, and camel isolates); Orthohepevirus B (comprising isolates from chicken); Orthohepevirus C (comprising isolates from rat, greater bandicoot, Asian musk shrew, ferret, and mink); and Orthohepevirus D (isolates from bat).
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Whereas the ICTV does not provide a classification below the species level, Smith et al. proposed to subdivide the Orthohepevirus A species into seven genotypes (gt). 11 Genotypes 1 and 2 only infect humans, mainly in endemic areas such as Asia, Africa, and Mexico. 7 Genotypes 3 and 4 include zoonotic strains that can infect both pigs and humans, but also include strains that have been isolated from rabbits, deer, and mongoose. Genotype 3 viruses are responsible for most autochthonous HEV infections in Europe, 4 whereas gt 4 is mainly found in Asia, where it causes sporadic cases of acute hepatitis E (AHE) in humans. 12 Strains isolated from wild boar are classified in gt 5 and 6, whereas isolates from camel are classified into gt 7.
Epidemiology and Transmission
HEV can spread by four different transmission modes: fecal-oral, food-borne, blood-borne, and vertical transmission (Fig. 2) . The fecal-oral route, mainly by ingestion of contaminated water, is the most common mode of transmission of HEV infection globally and is responsible for the majority of HEV outbreaks. 1, 13 Food-borne HEV transmission is achieved by consumption of raw or undercooked meat from infected animals, typically pigs and wild boar, or contaminated seafood. 4, [12] [13] [14] Not only meat products can be contaminated, given that HEV RNA has also been detected on leafy green vegetables and on field-grown strawberries, probably caused by the use of contaminated irrigation water and/or contaminated manure or compost. 15, 16 Vertical or perinatal transmission from mother to child has also been observed in developing countries. 17 Finally, blood transfusion-associated HEV transmission has not only been documented in several European countries, such as Great Britain, Germany, and France, [18] [19] [20] but also in Canada 21 and Japan. 22 A recent study in the UK involving 225,000 blood donations showed that 0.035% of these were viremic. 20 Approximately 42% of people who were transfused with HEV-RNA-positive blood preparations became viremic or developed anti-HEV antibodies. Recipient immunosuppression extended the duration of viremia, which led to persistent infection in the patient group receiving the highest degree of immunosuppression. Although donated blood is not routinely tested for the presence of HEV in the United States, to our knowledge, only 1 post-transfusion HEV case has thus far been reported, as well as at least 1 suspected case. 23, 24 HEV causes around 20 million infections per year resulting in around 3 million acute illnesses and 70,000 deaths annually worldwide. 25 HEV infection is a major cause of epidemic and acute sporadic hepatitis in many areas of Asia, Africa, and Mexico, where HEV is considered endemic and where transmission is instigated by lack of good sanitary infrastructure and poor hygienic practices.
In Europe and the United States, HEV was considered nonendemic with only sporadic nonepidemic incidents that are mainly associated with travel to endemic areas. 4 At first sight, during the past decade, the incidence of non-travel-associated HEV infections seems to be increased. 4 It is believed that zoonotic or food-borne transmission, resulting from close environmental contact with farm animals or consumption of contaminated produce, are the major transmission routes in European countries and the United States. 4, 14, 26, 27 However, an additional factor that might explain the seeming increase of autochthonous HEV infection in the Western world is the fact that it was, and probably still is, frequently misdiagnosed as drug-induced liver injury. 18, 28 Absence of routine screening practices and lack of sensitive assays only contributed to this. The prevalence of anti-HEV immuinoglobulin G in European healthy individuals ranges, depending on the age, region, exposure risk, and diagnostic assay used, between 5% and 52.5%. 4 Studies in the United States indicate a seroprevalence ranging between 6% and 26%, 6, 24, 29, 30 which is more or less in line with what is observed in most European countries.
Acute and Chronic HEV Infection
Not all HEV-infected individuals develop overt clinical disease. Accordingly, although a significant proportion of individuals in many industrialized countries are seropositive for HEV antibodies, they have no known history of hepatic disease. 26, 29 In symptomatic cases, the incubation period ranges from 2 to 8 weeks, with a mean of 40 days. Initial symptoms of AHE are typically nonspecific and include flu-like myalgia, arthralgia, weakness, abdominal pain, and vomiting. Some patients have jaundice, itching, pale stools, darkened urine, and abnormal liver function tests (increased levels of alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyltransferese, alkaline phosphatase, and bilirubin). 31 In developing countries, overall mortality rates are generally low (approximately 0.5%-4.0%), increase in young infants under 2 years, and peak in pregnant women that are in their third trimester (10%-20%). A significant proportion of pregnant women with AHE (up to 70%) progress to acute liver failure with a short preencephalopathy period, rapid development of cerebral edema, and high occurrence of disseminated intravascular coagulation. 32 Complications of HEV infection during pregnancy depend on disease severity and may result in fetal and/or maternal mortality, abortion, premature delivery, or death of a live-born baby soon after birth. Complications during pregnancy appear to be limited to gt 1 and 2 infections. Although this may be related to a greater virulence of these human-specific viruses, hormonal and immunological changes during pregnancy probably also contribute. 33 Reduced expression of the progesterone receptor and a weaker HEV-specific T-cell Fig. 1 . Genomic organization. The HEV genome is approximately 7.2 kb long and is organized in three ORFs. ORF1 is translated from the genomic RNA into a polyprotein that contains the nonstructural protein(s) with methyltransferase (MT), papa€ ın-like cysteine protease (Pro), helicase (Hel), and RNA-dependent RNA polymerase (Pol) activity. In addition, it contains a Y-domain and a macro domain (X), which have unknown function. A polyproline hinge region containing hypervariable sequences (PPR-HVR) can be observed in between the protease and the macro domain. ORF2 and ORF3 are translated from a 2.2-kb subgenomic RNA. ORF2 encodes the viral capsid protein, whereas ORF3 encodes for a protein that is probably involved in viral replication, morphogenesis, and egress. Abbreviation: HVR, hypervariable region; PPR, polyproline region.
response have been correlated with severity and mortality of HEV pregnant women. 33, 34 People with underlying liver disease (e.g., in the case of chronic HBV infection) may experience exacerbation, including liver failure and increased mortality upon AHE infection. 35, 36 Several cases of fulminant hepatitis were recently reported in Italy and France. 37, 38 Although, for many years, HEV was considered as a virus responsible for acute hepatitis that does not evolve to chronicity, certain HEV-infected individuals may develop chronic infection. These especially include patients that are immunocompromised owing to immunosuppressive therapy in and beyond the context of solid organ transplantation, hematological disorders, or HIV infection. [39] [40] [41] [42] [43] [44] [45] This is not surprising given that T cells play an essential role in clearance of HEV infection. 46 However, although several cases of chronic HEV infection have been described in HIV patients in the UK, 47 Spain, 48 Switzerland, 40 and France, 49 the overall risk of developing chronic disease in Europe is relatively low, considering the high risk of exposure. 42, 50 Nevertheless, HEV/HIV-coinfected patients with low CD4 1 T-cell count may rapidly develop liver cirrhosis. 48 Chronic HEV in organ transplant recipients has been well documented in many European countries. In a retrospective analysis in France, 8 of 14 organ transplant patients who acquired an HEV infection progressed to chronicity. 41 In The Netherlands, 2 cases of liver transplant (LT) patients developed chronic HEV, of whom 1 evolved to cirrhosis. 39 Both patients needed retransplantation within 5-7 years. Two additional cases of chronic HEV in an LT setting were reported in Germany. 51 Since 2011, more than 29 cases of chronic HEV were reported in LT patients in Europe. [52] [53] [54] [55] [56] Additional chronic HEV infections were reported in the context of kidney transplantation, 41, 52, 53, [55] [56] [57] pancreas transplantation, 41 lung transplantation, 53, 58 heart transplantation, 53, 59, 60 and allogeneic hematopoietic stem cell transplantation. 61 In contrast to the vast amount of documented chronic HEV infections in transplant patients in Europe, there are only limited data available from the United States and Canada. In this regard, in two studies involving pediatric patients in Montreal, persistent elevation of serum aminotransferases after liver or bone marrow transplantation was, in most cases, attributed to chronic HEV infection. 62, 63 Two cases of chronic HEV infection were reported in New York, one in the context of pancreas-kidney transplantation 64 and 1 patient receiving medication that interferes with the immune system. 44 An additional case was reported in Chicago post-LT. 65 Seven additional autochthonous acute and chronic HEV transplant cases were reported throughout the United States during the period from 2005 to 2012. 66 Nevertheless, two recent studies highlighted that only 1.9%-4.8% of in total 566 transplant patients showed evidence of post-transplant HEV infection, but none of these developed chronicity. 67, 68 Extrahepatic manifestations have also been associated with HEV infection. Renal complications, including decreased glomerular filtration rate, glomerulonephritis, and cryoglobulinemia, were observed in solid organ transplant patients that acquired acute or chronic HEV. 69 In a study in two hospitals in the UK and France, approximately 5% acute and chronic HEV patients developed neurological disorders, such as inflammatory polyradiculopathy, Guillain-Barr e syndrome (GBS), bilateral brachial neuritis, encephalitis, or ataxia/proximal myopathy. 70 Association between GBS and acute HEV infection has also been demonstrated in Germany and The Netherlands, where approximately 5% of GBS patients had proven autochthonous acute HEV infection. 71, 72 Other documented extrahepatic manifestations include rash, arthralgia, hematological disorders, and Parsonage Turner syndrome.
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Treatment
Immune competent persons are usually able to spontaneously clear an acute HEV infection. Hence, most AHE infections do not require treatment. 56 However, pregnant women, people with pre-existing liver disease, and immune suppressed transplant patients may require therapy.
Reduction of immunosuppressive therapy in transplant recipients leads to HEV clearance in approximately 30% of HEV-infected transplant recipients. 55, 76, 77 If this strategy is not tolerated or if it does not achieve the desirable results, either treatment with pegylated interferon alpha (Peg-IFN-a) or ribavirin (RBV) could be started (Table  1) . In principle, antiviral therapy should be started if viral clearance is not attained within 3-6 months.
Peg-IFN-a was first described for treatment of chronic HEV in 2010. 76, 78 Although a 3-to 12-month therapy usually, but not always, resulted in a sustained virological response (SVR), Peg-IFN-a therapy remains tedious in organ transplant patients because of the severe side effects and potential graft rejection. Especially, heart and kidney transplant patients are at high risk of graft rejection. RBV therapy should be the first-choice antiviral treatment in transplant patients.
RBV inhibits HEV replication through depletion of cellular guanosine triphosphate pools and is moderately synergistic with interferon (IFN) therapy. 79 RBV therapy for at least 3 months usually results in clearance of infection. 56, 58, 80, 81 Although RBV therapy seems to be very effective, up to 38% of treated patients do not show an SVR or even relapse during therapy. 56, 80, 82, 83 Usually, this is linked to RBV dose reductions because of severe anemia, but also a mutation in the viral polymerase (G1634R), which results in more-efficient replication, was linked to partial or nonresponse. 82 Because RBV is contraindicated during pregnancy owing to its teratogenicity and also PEG-IFN-a cannot be used in this setting, novel antiviral strategies are highly needed. 84 
Prevention of HEV Infection
Improved personal hygiene and sanitation has led to a marked reduction in the incidence of HEV infection, mainly in developing countries. However, pigs represent the major animal reservoir of HEV in industrialized countries and are most likely the main cause of infection. Surveys of European and U.S. pig farms indicate that a large proportion of herds have evidence of recent or ongoing HEV infection. 14, 27 Although detection and isolation of infected pigs and pork meat could represent the first step in the prevention of HEV spread, this strategy is most likely practically and economically not achievable. However, adequate cooking of pork meat by heating to an internal temperature of 718C for, depending on the food type and fat content, 1-20 minutes completely inactivates HEV and consequently reduces the possibility of infection by ingestion. 85 There is molecular evidence of the presence of HEV in wastewater runoff from swine farms. This runoff might reach drinking water and cause water-borne infections 13 or it may contaminate irrigation water used by fruit and vegetable farmers. 16 Therefore, frequent monitoring of waste runoff could reduce the incidence of HEV infection.
Polyclonal anti-HEV immunoglobulin acquired during natural infection and monoclonal antibodies generated by phage display can prevent a subsequent HEV infection (reviewed in a previous work 86 ). Because HEV has only one serotype, it is expected that a vaccine will be equally protective against any of the four HEV genotypes. In 2007, an aluminum hydroxide-adjuvanted vaccine, containing a truncated form of the HEV capsid protein, was proven effective in prevention of hepatitis E infection. 8 This vaccine trial, conducted in 2,000 young and healthy individuals from the Nepalese army (99.6% of whom were men), demonstrated that three doses of the recombinant vaccine provides 95.5% protection in a region where only gt 1 HEV has been isolated. Recently, a phase III trial of another recombinant capsid vaccine expressed in Escherichia coli (designated HEV 239 or Hecolin V R ) was conducted in China (involving >100,000 men and women; age 15-60 years) and was found to have an efficacy of 100% within 1 year postvaccination. 9 A follow-up study recently indicated that this vaccine provides protection for at least up to 4.5 years. 87 Hecolin V R is currently only licensed in China, and although its efficacy was shown against HEV of gt 1 and 4, a formal proof for its activity against gt 2 and 3 is still lacking.
Summary and Conclusions
HEV is considered as an emerging problem in Europe, but most likely there is only an increased awareness of this virus being a potential etiological agent for chronic and progressive hepatitis in transplant patients. 4 As with in Europe, HEV is endemic in the U.S. population and HEV circulates abundantly among North American pig herds.
14 Therefore it is surprising that recent studies denote that acute HEV occurs in U.S. transplant populations, but it does not seem to be a major cause of unexplained chronic hepatitis. [64] [65] [66] [67] [68] 88 More and larger studies are needed to confirm this discrepancy. The reason for this potential inconsistency remains unclear and warrants further investigation. Two reports suggest that there is a 24 Differences in therapeutic protocols and/or culinary practices may have an impact on the course of infection. Interestingly, calcineurin inhibitors, such as tacrolimus and cyclosporine, two widely used immunosuppressants, were shown to stimulate HEV replication whereas mycophenolic acid had an inhibitory effect. 92 Immunosuppressive therapy with mammalian target of rapamycin (mTOR) inhibitors, such as rapamycin and everolimus, also seems to facilitate HEV replication. 93 These data highlight that the type of immunosuppressive therapy could have an influence on the clinical course of HEV infection in a transplant setting.
A recent study in the UK showed that a limited amount of voluntary blood donors are actively infected with HEV, which poses an additional risk for transplant patients. 20 A study wherein nearly 2,000 U.S. blood donations were screened for the presence of HEV RNA came out negative, 24 but the size of this study was most likely not large enough, considering that only 0.035% of UK samples were viremic.
Blood transfusion-associated HEV infection has been documented in several industrialized countries, including the United States, [18] [19] [20] [21] [22] [23] but it remains to be determined how efficiently the virus present in blood products can be transmitted, and whether the different processing protocols utilized in blood transfusion centers are adequate enough to minimize or even eliminate the risk of viral transmission. The outcome of such studies will highlight whether or not routine screening of blood products for the presence of HEV RNA should be implemented. Meanwhile, a limited proportion of screened blood products could be selected for immunocompromised patients.
In any case, patients with increased risk of infection could easily minimize their exposure by simple dietary practices, such as thorough cooking of pork and game meat and extensive washing and/or pealing of vegetables and fruits. Recently, HEV was also detected in a variety of other animals, such as rabbits, that are routinely consumed, but it remains unclear whether this poses a hazard for humans. Meanwhile it remains important to screen for the presence HEV RNA (using a highly sensitive reverse-transcriptase polymerase chain reaction) in patients with unexplained hepatitis, especially in those suffering from any kind of immune suppression.
